• FirefoxInstall the new Firefox »
  •  Dow Up0.12% Nasdaq Up0.37%

    Alimera Sciences, Inc. (ALIM)

    4.33 Down 0.05(1.14%) 11:39AM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Alimera Sciences, Inc.
    6120 Windward Parkway
    Suite 290
    Alpharetta, GA 30005
    United States - Map
    Phone: 678-990-5740
    Fax: 678-990-5744
    Website: http://www.alimerasciences.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:70

    Business Summary 

    Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that uses the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alimera Sciences, Inc.

    Corporate Governance 
    Alimera Sciences, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 10. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 10; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Charles Daniel Myers , 61
    Co-Founder, Chief Exec. Officer, Pres and Director
    Mr. Richard S. Eiswirth Jr., 47
    Chief Financial Officer, Chief Operating Officer, Treasurer and Sec.
    Dr. Kenneth Green Ph.D., 57
    Chief Scientific Officer and Sr. VP
    Mr. David R. Holland , 51
    Co-Founder and Sr. VP of Sales & Marketing
    Ms. Susan H. Caballa , 71
    Sr. VP of Regulatory & Medical Affairs
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders